PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11358821-4	2001	Addition of 0.1-10 microM doxorubicin to these cells led to a concentration- and time-dependent inhibition of total iPLA(2), as measured using (16:0, [(3)H]18:1) plasmenylcholine and phosphatidylcholine substrates in the presence or absence of calcium.	Phosphatidylcholines	183-202	phospholipase A2 group VI	Rattus norvegicus	116-123	
10827200-7	2000	Analysis of molecular species of microsomal phosphatidylcholine and phosphatidylethanolamine by electron spray tandem mass spectrometry revealed that the enrichment of oleoyl moieties was altered by the treatment of iPLA(2) antagonist.	Phosphatidylcholines	44-63	phospholipase A2 group VI	Rattus norvegicus	216-223	
10461922-4	1999	Under optimal conditions, the iPLA2 revealed the following substrate preference toward the fatty acid chain in the sn-2 position of phosphatidylcholine: linoleoyl > palmitoyl > oleoyl > arachidonoyl.	Phosphatidylcholines	132-151	phospholipase A2 group VI	Rattus norvegicus	30-35	
16286468-1	2006	Studies involving pharmacologic inhibition or transient reduction of Group VIA phospholipase A2 (iPLA2beta) expression have suggested that it is a housekeeping enzyme that regulates cell 2-lysophosphatidylcholine (LPC) levels, rates of arachidonate incorporation into phospholipids, and degradation of excess phosphatidylcholine (PC).	Phosphatidylcholines	193-212	phospholipase A2 group VI	Rattus norvegicus	97-106	
9746498-5	1998	With phosphatidylcholine as substrate, TNF-alpha decreased both cytosolic and membrane-associated iPLA2 activities.	Phosphatidylcholines	5-24	phospholipase A2 group VI	Rattus norvegicus	98-103